|
1
|
Forman D and Burley VJ: Gastric cancer:
Global pattern of the disease and an overview of environmental risk
factors. Best Pract Res Clin Gastroenterol. 20:633–649. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ueda S, Kuji I, Shigekawa T, Takeuchi H,
Sano H, Hirokawa E, Shimada H, Suzuki H, Oda M, Osaki A and Saeki
T: Optical imaging for monitoring tumor oxygenation response after
initiation of single-agent bevacizumab followed by cytotoxic
chemotherapy in breast cancer patients. PLoS One. 9:e987152014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mita M, Gordon M, Rosen L, Kapoor N, Choy
G, Redkar S, Taverna P, Oganesian A, Sahai A, Azab M, et al: Phase
1B study of amuvatinib in combination with five standard cancer
therapies in adults with advanced solid tumors. Cancer Chemother
Pharmacol. 74:195–204. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Le XF and Bast RC Jr: Src family kinases
and paclitaxel sensitivity. Cancer Biol Ther. 12:260–269. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu G, Qin XQ, Guo JJ, Li TY and Chen JH:
AKT/ERK activation is associated with gastric cancer cell
resistance to paclitaxel. Int J Clin Exp Pathol. 7:1449–1458.
2014.PubMed/NCBI
|
|
6
|
Zanetta G, Fei F and Mangioni C:
Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the
treatment of squamous cell cervical cancer: The experience of
Monza. Semin Oncol. 27 1 Suppl 1:S23–S27. 2000.
|
|
7
|
Murray S, Briasoulis E, Linardou H,
Bafaloukos D and Papadimitriou C: Taxane resistance in breast
cancer: Mechanisms, predictive biomarkers and circumvention
strategies. Cancer Treat Rev. 38:890–903. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jiang C, Chen X, Alattar M, Wei J and Liu
H: MicroRNAs in tumorigenesis, metastasis, diagnosis and prognosis
of gastric cancer. Cancer Gene Ther. 22:291–301. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tutar L, Tutar E, Özgür A and Tutar Y:
Therapeutic targeting of microRNAs in cancer: Future perspectives.
Drug Dev Res. 76:382–388. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu X, Li J, Qin F and Dai S: miR-152 as a
tumor suppressor microRNA: Target recognition and regulation in
cancer. Oncol Lett. 11:3911–3916. 2016.PubMed/NCBI
|
|
12
|
Naidu S, Magee P and Garofalo M:
MiRNA-based therapeutic intervention of cancer. J Hematol Oncol.
8:682015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Misso G, Di Martino MT, de Rosa G, Farooqi
AA, Lombardi A, Campani V, Zarone MR, Gullà A, Tagliaferri P,
Tassone P and Caraglia M: Mir-34: A new weapon against cancer? Mol
Ther Nucleic Acids. 3:e1942014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu G, Jiang C, Li D, Wang R and Wang W:
MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in
gastric cancer. Tumour Biol. 35:9801–9806. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Polanowska J, Le Cam L, Orsetti B, Vallés
H, Fabbrizio E, Fajas L, Taviaux S, Theillet C and Sardet C: Human
E2F5 gene is oncogenic in primary rodent cells and is amplified in
human breast tumors. Genes Chromosomes Cancer. 28:126–130. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kothandaraman N, Bajic VB, Brendan PN,
Huak CY, Keow PB, Razvi K, Salto-Tellez M and Choolani M: E2F5
status significantly improves malignancy diagnosis of epithelial
ovarian cancer. BMC Cancer. 10:642010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao J, Wu XY, Ling XH, Lin ZY, Fu X, Deng
YH, He HC and Zhong W: Analysis of genetic aberrations on
chromosomal region 8q21-24 identifies E2F5 as an oncogene with copy
number gain in prostate cancer. Med Oncol. 30:4652013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiang Y, Yim SH, Xu HD, Jung SH, Yang SY,
Hu HJ, Jung CK and Chung YJ: A potential oncogenic role of the
commonly observed E2F5 overexpression in hepatocellular carcinoma.
World J Gastroenterol. 17:470–477. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Macfarlane LA and Murphy PR: MicroRNA:
Biogenesis, function and role in cancer. Curr Genomics. 11:537–561.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang J, Li S, Li L, Li M, Guo C, Yao J
and Mi S: Exosome and exosomal microRNA: Trafficking, sorting, and
function. Genomics Proteomics Bioinformatics. 13:17–24. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen CZ: MicroRNAs as oncogenes and tumor
suppressors. N Engl J Med. 353:1768–1771. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cao W, Fan R, Wang L, Cheng S, Li H, Jiang
J, Geng M, Jin Y and Wu Y: Expression and regulatory function of
miRNA-34a in targeting survivin in gastric cancer cells. Tumour
Biol. 34:963–971. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
McKenzie JA and Grossman D: Role of the
apoptotic and mitotic regulator survivin in melanoma. Anticancer
Res. 32:397–404. 2012.PubMed/NCBI
|
|
25
|
Li XY, Wen JY, Jia CC, Wang TT, Li X, Dong
M, Lin QU, Chen ZH, Ma XK, Wei LI, et al: MicroRNA-34a-5p enhances
sensitivity to chemotherapy by targeting AXL in hepatocellular
carcinoma MHCC-97L cells. Oncol Lett. 10:2691–2698. 2015.PubMed/NCBI
|
|
26
|
Chen HZ, Tsai SY and Leone G: Emerging
roles of E2Fs in cancer: An exit from cell cycle control. Nat Rev
Cancer. 9:785–797. 2009. View
Article : Google Scholar : PubMed/NCBI
|
